In particular, SP-triggered release of PGD2 and pLT from PBLs seems to be promising estimators of metabolic hyperactivity of PBLs from MCAD patients and may aid in distinguishing MCAD patients from healthy subjects and perhaps other diseases. This evidence concerns the gene PTGDS and medium chain acyl-CoA dehydrogenase deficiency.